Dublin-based medical and health care research company Alltracel Pharmaceuticals today reported half year revenue of €8.3 million.
In a trading statement, the company - which specialises in oral care and cholesterol-control devices - said the results were in line with expectations and that it expects full-year revenues to be in excess of €21 million.
Alltracel said its m-doc partnership programme continues to expand as co-branded agreements were concluded for leading local brands in Brazil and Holland deals.
The company also said its oral care private label revenues were marginally ahead of expectations.
READ MORE
It announced the appointment of Dr Patrick Wall to the newly created position of chairman of the group's Scientific Advisory Board.